AMPKα2 Suppresses Murine Embryonic Fibroblast Transformation and Tumorigenesis

Genes and Cancer

Volumn 3, Issue 1, 2012, Pages 51-62

  Phoenix, Kathryn N ^a   Devarakonda, Charan V ^a   Fox, Melissa M ^a   Stevens, Laura E ^a   Claffey, Kevin P ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

AMPK; cancer; p53; transformation

Indexed keywords

AMP ACTIVATED KINASE ALPHA 1; AMP ACTIVATED KINASE ALPHA 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

MURINAE; MUS;

EID: 84868636853     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912452883     Document Type: Article

References (51)

1. Davies SP,Hawley SA,Woods A,Carling D,Haystead TA,Hardie DG.Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure.Eur J Biochem. 1994;223:351-7.
2. Hardie DG.AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.Nat Rev Mol Cell Biol. 2007;8:774-85.
3. Woods A,Salt I,Scott J,Hardie DG,Carling D.The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro.FEBS Lett. 1996;397:347-51.
4. Stapleton D,Mitchelhill KI,Gao G.Mammalian AMP-activated protein kinase subfamily.J Biol Chem. 1996;271:611-4.
5. Salt I,Celler JW,Hawley SA.AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform.Biochem J. 1998;334 (Pt 1): 177-87.
6. Viollet B,Andreelli F,Jorgensen SB.Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models.Biochem Soc Trans. 2003;31:216-9.
7. Viollet B,Andreelli F,Jorgensen SB.The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity.J Clin Invest. 2003;111:91-8.
8. Foretz M,Ancellin N,Andreelli F.Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver.Diabetes. 2005;54:1331-9.
9. Villena JA,Viollet B,Andreelli F,Kahn A,Vaulont S,Sul HS.Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit.Diabetes. 2004;53:2242-9.
10. Viollet B,Athea Y,Mounier R.AMPK: lessons from transgenic and knockout animals.Front Biosci. 2009;14:19-44.
11. Goirand F,Solar M,Athea Y.Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice.J Physiol. 2007;581:1163-71.
12. Hardie DG.AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer.Biochem Soc Trans. 2011;39:1-13.
13. Wang W,Guan KL.AMP-activated protein kinase and cancer.Acta Physiol (Oxf). 2009;196:55-63.
14. Kuhajda FP.AMP-activated protein kinase and human cancer: cancer metabolism revisited.Int J Obes (Lond). 2008;32 (Suppl 4): S36-41.
15. Tomimoto A,Endo H,Sugiyama M.Metformin suppresses intestinal polyp growth in ApcMin/+ mice.Cancer Sci. 2008;99:2136-41.
16. Liu J,Li M,Song B,et al.Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.Urol Oncol. 2011;:.
17. Cell Cycle. Liu BFan ZEdgerton SM, ed. 2009:2031-40.
18. Janjetovic K,Harhaji-Trajkovic L,Misirkic-Marjanovic M.In vitro and in vivo anti-melanoma action of metformin.Eur J Pharmacol. 2011;668:373-82.
19. Isakovic A,Harhaji L,Stevanovic D.Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.Cell Mol Life Sci. 2007;64:1290-302.
20. Green AS,Chapuis N,Maciel TT.The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.Blood. 2010;116:4262-73.
21. Gotlieb WH,Saumet J,Beauchamp MC.In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.Gynecol Oncol. 2008;110:246-50.
22. Garcia-Gil M,Bertini F,Pesi R,Voccoli V,Tozzi MG,Camici M.5'-Amino-4-imidazolecarboxamide riboside induces apoptosis in human neuroblastoma cells via the mitochondrial pathway.Nucleosides Nucleotides Nucleic Acids. 2006;25:1265-70.
23. Vazquez-Martin A,Oliveras-Ferraros C,Lopez-Bonet E,Menendez JA.AMPK: evidence for an energy-sensing cytokinetic tumor suppressor.Cell Cycle. 2009;8:3679-83.
24. Bowker SL,Majumdar SR,Veugelers P,Johnson JA.Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.Diabetes Care. 2006;29:254-8.
25. Evans JM,Donnelly LA,Emslie-Smith AM,Alessi DR,Morris AD.Metformin and reduced risk of cancer in diabetic patients.BMJ. 2005;330:1304-5.
26. Shaw RJ,Kosmatka M,Bardeesy N.The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.Proc Natl Acad Sci U S A. 2004;101:3329-35.
27. Jenne DE,Reimann H,Nezu J.Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.Nat Genet. 1998;18:38-43.
28. Yoo LI,Chung DC,Yuan J.LKB1: a master tumour suppressor of the small intestine and beyond.Nat Rev Cancer. 2002;2:529-35.
29. Gurumurthy S,Hezel AF,Sahin E,Berger JH,Bosenberg MW,Bardeesy N.LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis.Cancer Res. 2008;68:55-63.
30. Hadad SM,Baker L,Quinlan PR.Histological evaluation of AMPK signalling in primary breast cancer.BMC Cancer. 2009;9:307.
31. Imamura K,Ogura T,Kishimoto A,Kaminishi M,Esumi H.Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line.Biochem Biophys Res Commun. 2001;287:562-7.
32. Jones RG,Plas DR,Kubek S.AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.Mol Cell. 2005;18:283-93.
33. Okoshi R,Ozaki T,Yamamoto H.Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress.J Biol Chem. 2008;283:3979-87.
34. Wang S,Song P,Zou MH.Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1.J Biol Chem. 2012;287:8001-12.
35. Hahn WC,Weinberg RA.Rules for making human tumor cells.N Engl J Med. 2002;347:1593-603.
36. Boland CR,Ricciardiello L.How many mutations does it take to make a tumor?.Proc Natl Acad Sci U S A. 1999;96:14675-7.
37. Hahn WC,Counter CM,Lundberg AS,Beijersbergen RL,Brooks MW,Weinberg RA.Creation of human tumour cells with defined genetic elements.Nature. 1999;400:464-8.
38. Newbold R.Cancer: mutant ras proteins and cell transformation.Nature. 1984;310:628-9.
39. Newbold RF,Overell RW.Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene.Nature. 1983;304:648-51.
40. Serrano M,Lin AW,McCurrach ME,Beach D,Lowe SW.Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.Cell. 1997;88:593-602.
41. Luo Z,Zang M,Guo W.AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.Future Oncol. 2010;6:457-70.
42. Zhou J,Huang W,Tao R.Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells.Oncogene. 2009;28:1993-2002.
43. Sprenkle AB,Davies SP,Carling D,Hardie DG,Sturgill TW.Identification of Raf-1 Ser621 kinase activity from NIH 3T3 cells as AMP-activated protein kinase.FEBS Lett. 1997;403:254-8.
44. Costanzo-Garvey DL,Pfluger PT,Dougherty MK.KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity.Cell Metab. 2009;10:366-78.
45. Laderoute KR,Amin K,Calaoagan JM.5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments.Mol Cell Biol. 2006;26:5336-47.
46. Inoki K,Ouyang H,Zhu T.TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.Cell. 2006;126:955-68.
47. Sherr CJ.The INK4a/ARF network in tumour suppression.Nat Rev Mol Cell Biol. 2001;2:731-7.
48. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-74.
49. Hallstrom TC,Mori S,Nevins JR.An E2F1-dependent gene expression program that determines the balance between proliferation and cell death.Cancer Cell. 2008;13:11-22.
50. Kim YH,Liang H,Liu X.AMPKalpha modulation in cancer progression: multilayer integrative transcriptome analysis in Asian gastric cancer.Cancer Res. 2012;72:2512-21.
51. Phoenix KN,Vumbaca F,Claffey KP.Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.Breast Cancer Res Treat. 2009;113:101-11.